Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer

Gut24.50
Volume: 67, Issue: 12, Pages: 2142 - 2155
Published: Dec 1, 2018
Abstract
Objective null Extensive molecular heterogeneity of pancreatic ductal adenocarcinoma (PDA), few effective therapies and high mortality make this disease a prime model for advancing development of tailored therapies. The p16-cyclin D-cyclin-dependent kinase 4/6-retinoblastoma (RB) protein (CDK4) pathway, regulator of cell proliferation, is deregulated in PDA. Our aim was to develop a novel personalised treatment strategy for PDA based on...
Paper Details
Title
Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
Published Date
Dec 1, 2018
Journal
Volume
67
Issue
12
Pages
2142 - 2155
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.